Which has preferable valuation and earnings, SGP or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is SGP or GPCR more profitable?

Structure Therapeutics' return on equity of -25.56% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% Structure Therapeutics N/A -25.56% -24.31%

Which has higher earnings & valuation, SGP or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is SGP or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% MBX Biosciences N/A -26.02% -24.94%

Do analysts rate MOR or SGP?

Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 66.54%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is MOR or SGP more profitable?

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Spyglass Pharma N/A -62.40% -24.83%

Spyglass Pharma (SGP) Competitors

$26.42 -0.51 (-1.89%)

As of 08/28/2026 04:00 PM Eastern

Compare

SGP vs. GPCR, MBX, TARS, ARQT, and MOR

Should you buy Spyglass Pharma stock or one of its competitors? Spyglass Pharma's main competitors and comparable companies include Structure Therapeutics (GPCR), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spyglass Pharma compare to Structure Therapeutics?

Spyglass Pharma (NASDAQ:SGP) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Structure Therapeutics' return on equity of -25.56% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Structure Therapeutics	N/A	-25.56%	-24.31%

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyglass Pharma presently has a consensus target price of $44.00, suggesting a potential upside of 66.54%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

In the previous week, Structure Therapeutics had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Structure Therapeutics' score of 1.32 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Structure Therapeutics	Positive

Summary

Structure Therapeutics beats Spyglass Pharma on 10 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to MBX Biosciences?

Spyglass Pharma (NASDAQ:SGP) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
MBX Biosciences	N/A	-26.02%	-24.94%

Spyglass Pharma presently has a consensus price target of $44.00, suggesting a potential upside of 66.54%. MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 22.22%. Given Spyglass Pharma's higher probable upside, research analysts clearly believe Spyglass Pharma is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, MBX Biosciences had 6 more articles in the media than Spyglass Pharma. MarketBeat recorded 7 mentions for MBX Biosciences and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat MBX Biosciences' score of 1.01 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
MBX Biosciences	Positive

Summary

MBX Biosciences beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Spyglass Pharma (NASDAQ:SGP) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Spyglass Pharma has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A

In the previous week, Tarsus Pharmaceuticals had 14 more articles in the media than Spyglass Pharma. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Tarsus Pharmaceuticals' score of 1.63 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Tarsus Pharmaceuticals	Very Positive

Spyglass Pharma currently has a consensus price target of $44.00, indicating a potential upside of 66.54%. Tarsus Pharmaceuticals has a consensus price target of $90.50, indicating a potential upside of 26.11%. Given Spyglass Pharma's higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyglass Pharma has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Summary

Tarsus Pharmaceuticals beats Spyglass Pharma on 9 of the 15 factors compared between the two stocks.

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Spyglass Pharma's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Spyglass Pharma	N/A	-62.40%	-24.83%

Arcutis Biotherapeutics has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

In the previous week, Arcutis Biotherapeutics had 14 more articles in the media than Spyglass Pharma. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Arcutis Biotherapeutics' score of 1.15 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Spyglass Pharma	Very Positive

Arcutis Biotherapeutics presently has a consensus target price of $35.57, indicating a potential upside of 49.59%. Spyglass Pharma has a consensus target price of $44.00, indicating a potential upside of 66.54%. Given Spyglass Pharma's higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Arcutis Biotherapeutics beats Spyglass Pharma on 9 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Spyglass Pharma had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Spyglass Pharma and 0 mentions for MorphoSys. Spyglass Pharma's average media sentiment score of 1.89 beat MorphoSys' score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Spyglass Pharma	Very Positive

Spyglass Pharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 66.54%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Spyglass Pharma	N/A	-62.40%	-24.83%

Summary

Spyglass Pharma beats MorphoSys on 9 of the 14 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$883.30M	$12.15B	$7.21B	$12.91B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-3.77	787.65	273.16	25.45
Price / Sales	N/A	755.49	625.22	90.88
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	3.80	11.97	12.98	6.14
Net Income	-$39.87M	$2.83B	$3.48B	$348.86M
7 Day Performance	-0.34%	0.39%	0.13%	-0.80%
1 Month Performance	16.29%	5.34%	7.08%	4.13%
1 Year Performance	N/A	6.05%	24.67%	15.17%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	2.6945 of 5 stars	$26.42 -1.9%	$44.00 +66.5%	N/A	$883.30M	N/A	N/A	65	Positive News
GPCR Structure Therapeutics	2.2018 of 5 stars	$49.65 +1.3%	$110.91 +123.4%	+145.4%	$3.46B	N/A	N/A	136	Positive News
MBX MBX Biosciences	2.5144 of 5 stars	$68.81 +3.6%	$77.00 +11.9%	+317.5%	$3.32B	N/A	N/A	N/A	News Coverage Positive News
TARS Tarsus Pharmaceuticals	3.751 of 5 stars	$72.22 -0.8%	$90.50 +25.3%	+22.5%	$3.17B	$451.36M	N/A	50	News Coverage Positive News
ARQT Arcutis Biotherapeutics	4.1273 of 5 stars	$25.00 +0.9%	$35.57 +42.3%	+53.2%	$3.14B	$376.07M	119.02	150	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. GPCR, MBX, TARS, ARQT, and MOR

How does Spyglass Pharma compare to Structure Therapeutics?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Summary

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Summary

How does Spyglass Pharma compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. GPCR, MBX, TARS, ARQT, and MOR

How does Spyglass Pharma compare to Structure Therapeutics?

Is SGP or GPCR more profitable?

Do institutionals & insiders hold more shares of SGP or GPCR?

Do analysts prefer SGP or GPCR?

Which has preferable valuation and earnings, SGP or GPCR?

Does the media favor SGP or GPCR?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Is SGP or MBX more profitable?

Do analysts prefer SGP or MBX?

Which has higher earnings & valuation, SGP or MBX?

Does the media prefer SGP or MBX?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Which has stronger valuation and earnings, SGP or TARS?

Does the media prefer SGP or TARS?

Do analysts prefer SGP or TARS?

Do institutionals & insiders believe in SGP or TARS?

Is SGP or TARS more profitable?

Summary

How does Spyglass Pharma compare to Arcutis Biotherapeutics?

Is ARQT or SGP more profitable?

Which has higher valuation and earnings, ARQT or SGP?

Does the media favor ARQT or SGP?

Do analysts recommend ARQT or SGP?

Summary

How does Spyglass Pharma compare to MorphoSys?

Do institutionals & insiders hold more shares of MOR or SGP?

Does the media favor MOR or SGP?

Which has stronger valuation & earnings, MOR or SGP?

Do analysts rate MOR or SGP?

Is MOR or SGP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools